TNFRSF9 and neoplasm: Treatment with an agonist of CD137 (expressed on tumor endothelial cells) monoclonal antibody increases the expression of ICAM-1, VCAM-1, and E-selectin on tumor endothelial cell surface promoting CD8+ T cells recruitment [40].